Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
MoonLake Immunotherapeutics
Market Cap
$930.32M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$938.35M
Gross Margin
94.73%
TTM Avg
99.96%
3Y Avg
49.98%
5Y Avg
33.32%
Market Cap
$942.38M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$912.83M
Gross Margin
65.08%
TTM Avg
65.58%
3Y Avg
65.74%
5Y Avg
65.17%
Market Cap
$969.98M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
50.00%
5Y Avg
50.00%
Market Cap
$886.18M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | $930.32M | 0.00% | 0.00% | 0.00% | 0.00% |
| CeriBell, Inc. (CBLL)vs › | $935.90M | 88.90% | 87.31% | 85.47% | 85.47% |
| Kura Oncology, Inc. (KURA)vs › | $938.35M | 94.73% | 99.96% | 49.98% | 33.32% |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $942.38M | 0.00% | 0.00% | 0.00% | 0.00% |
| HealthStream, Inc. (HSTM)vs › | $912.83M | 65.08% | 65.58% | 65.74% | 65.17% |
| Savara Inc. (SVRA)vs › | $953.94M | 0.00% | 0.00% | 0.00% | -2255.58% |
| Bioventus Inc. (BVS)vs › | $899.69M | 68.00% | 67.52% | 65.94% | 67.78% |
| Aktis Oncology, Inc. (AKTS)vs › | $969.98M | 100.00% | 100.00% | 50.00% | 50.00% |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $886.18M | 100.00% | 100.00% | 100.00% | 100.00% |
| Pacira BioSciences, Inc. (PCRX)vs › | $976.29M | 79.21% | 77.54% | 74.46% | 74.10% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
